Find clinical trials for Lung Cancer in Paris, Île-de-France
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Lung Cancer trials near Paris, Île-de-France, FRA:
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...
Phase 2
Paris, France and 83 other locations
This study aims to evaluate the efficacy and safety of DS-1062a in participants with metastatic, unresectable NSCLC having progressed on one, but not...
Phase 2
Villejuif, France
This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer...
Phase 2
Villejuif, France and 47 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Paris, France and 205 other locations
with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung ...
Phase 3
Paris, France and 139 other locations
This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, loca...
Phase 3
Boulogne-Billancourt, France and 170 other locations
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...
Phase 2
Paris, France and 122 other locations
over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-sma ...
Phase 1
Villejuif Cedex, France and 36 other locations
type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...
Phase 1, Phase 2
Paris, France and 123 other locations
The main aim of this study is to:evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investiga...
Phase 2
Paris Cedex 05, France and 79 other locations
Clinical trials
Research sites
Resources
Legal